Coherus Gets Goal Date On US Adalimumab Biosimilar
Firm Sees ‘Pent-Up Demand’ For Potential $18bn Humira Target
Executive Summary
A further FDA approval for a biosimilar to Humira could be on the cards, after Coherus revealed the agency’s goal date for its CHS-1420 adalimumab application.
You may also be interested in...
Coherus Insists Demand Is ‘Pent Up’ For On-Body Pegfilgrastim Biosimilar
California-Based Coherus BioSciences delved further into its plans and expectations for its proposed proprietary pegfilgrastim on-body device, as it also detailed continued pricing challenges for the pre-filled syringe formulation.
Coherus Aiming For More Than 10% Slice Of US Adalimumab Market
Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture at least 10% of the US market upon formation in 2023. Management summarized the firm’s expectations during the company’s fourth-quarter earnings call, which revealed a downturn in pegfilgrastim sales and profitability.
Keeping Track: Novartis Entresto Wins Expanded Heart Failure Claim; Padcev, Vicineum Seek Bladder Cancer Approvals
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker